Effect of glucocorticoid receptor gene polymorphisms in Guillain-Barré syndrome

Journal of the Peripheral Nervous System

Volumn 14, Issue 2, 2009, Pages 75-83

  Dekker, Marieke J H J ^a   Van Den Akker, Erica L T ^a   Koper, Jan Willem ^a   Manenschijn, Laura ^a   Geleijns, Karin ^a   Ruts, Liselotte ^a   Van Rijs, Wouter ^a   Tio Gillen, Anne P ^a   Van Doorn, Pieter A ^a   Lamberts, Steven W J ^a   Jacobs, Bart C ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Auto immune disease; Glucocorticoid receptor; Guillain Barr syndrome; Single nucleotide polymorphism

Indexed keywords

AMANTADINE; GANGLIOSIDE GD 1A; GANGLIOSIDE GM1 ANTIBODY; GLUCOCORTICOID RECEPTOR; IMMUNOGLOBULIN; METHYLPREDNISOLONE;

ADOLESCENT; ADULT; AGED; ALLELE; ANTIBODY BLOOD LEVEL; ARTICLE; BCL 1 GENE; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE PREDISPOSITION; FATIGUE; FEMALE; GENE; GENETIC POLYMORPHISM; GENOTYPE; GUILLAIN BARRE SYNDROME; HAPLOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; MUSCLE WEAKNESS; OUTCOME ASSESSMENT; PHENOTYPE; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; SINGLE NUCLEOTIDE POLYMORPHISM; TTHIIII GENE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CHILD; CHILD, PRESCHOOL; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GUILLAIN-BARRE SYNDROME; HAPLOTYPES; HUMANS; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; RECEPTORS, GLUCOCORTICOID; SEQUENCE ANALYSIS, DNA; WALKING; YOUNG ADULT;

EID: 69249145190     PISSN: 10859489     EISSN: 15298027     Source Type: Journal    
DOI: 10.1111/j.1529-8027.2009.00216.x     Document Type: Article

References (36)

1. Ang CW, Jacobs BC, Laman JD (2004). The Guillain-Barre syndrome: a true case of molecular mimicry. Trends Immunol 25:61-66. (Pubitemid 38167486)
2. Asbury AK, Cornblath DR (1990). Assessment of current diagnostic criteria for Guillain-Barre syndrome. Ann Neurol 27:S21-S24. (Pubitemid 20178648)
3. Boumpas DT, Chrousos GP, Wilder RL, Cupps TR, Balow JE (1993). Glucocorticoid therapy for immune-mediated diseases: basic and clinical correlates. Ann Intern Med 119:1198-1208.
4. Chrousos GP (1995). The hypothalamic-pituitary-adrenal axis and immune-mediated inflammation. N Engl J Med 332:1351-1362.
5. Derijk RH, Schaaf MJ, Turner G, Datson NA, Vreugdenhil E, Cidlowski J, de Kloet ER, Emery P, Sternberg EM, Detera- Wadleigh SD (2001). A human glucocorticoid receptor gene variant that increases the stability of the glucocorticoid receptor beta-isoform mRNA is associated with rheumatoid arthritis. J Rheumatol 28:2383-2388. (Pubitemid 33031964)
6. Elenkov IJ, Chrousos GP (2002). Stress hormones, proinflammatory and antiinflammatory cytokines, and autoimmunity. Ann N Y Acad Sci 966:290-303.
7. Franchimont D (2004). Overview of the actions of glucocorticoids on the immune response: a good model to characterize new pathways of immunosuppression for new treatment strategies. Ann N Y Acad Sci 1024:124-137.
8. Garssen MP, Bussmann JB, Schmitz PI, Zandbergen A, Welter TG, Merkies IS, Stam HJ, van Doorn PA (2004). Physical training and fatigue, fitness, and quality of life in Guillain-Barre syndrome and CIDP. Neurology 63:2393-2395. (Pubitemid 40024359)
9. Garssen MP, Schmitz PI, Merkies IS, Jacobs BC, van der Mech ́ e FG, van Doorn PA (2006). Amantadine for treatment of fatigue in Guillain-Barre syndrome: a randomised, double blind, placebo controlled, crossover trial. J Neurol Neurosurg Psychiatry 77:61-65.
10. Garssen MP, van Koningsveld R, van Doorn PA, Merkies IS, Scheltens-de Boer M, van Leusden JA, van Schaik IN, Linssen WH, Visscher F, Boon AM, Faber CG, Meulstee J, Prick MJ, van den Berg LH, Franssen H, Hiel JA, van den Bergh PY, Sindic CJ (2007). Treatment of Guillain-Barre syndrome with mycophenolate mofetil: a pilot study. J Neurol Neurosurg Psychiatry 78:1012-1013. (Pubitemid 47310849)
11. Geleijns K, Laman JD, van Rijs W, Tio-Gillen AP, Hintzen RQ, van Doorn PA, Jacobs BC (2005). Fas polymorphisms are associated with the presence of anti-ganglioside antibodies in Guillain-Barre syndrome. J Neuroimmunol 161:183-189. (Pubitemid 40340887)
12. Geleijns K, Roos A, Houwing-Duistermaat JJ, van Rijs W, Tio- Gillen AP, Laman JD, van Doorn PA, Jacobs BC (2006). Mannose-binding lectin contributes to the severity of Guillain- Barre syndrome. J Immunol 177:4211-4217. (Pubitemid 44359957)
13. Greenwood RJ, Newsom-Davis J, Hughes RA, Aslan S, Bowden AN, Chadwick DW, Gordon NS, McLellan DL, Millac P, Stott RB, Armitage P (1984). Controlled trial of plasma exchange in acute inflammatory polyradiculoneuropathy. Lancet 1:877-879. (Pubitemid 14132390)
14. Heiduschka P, Thanos S (2006). Cortisol promotes survival and regeneration of axotomised retinal ganglion cells and enhances effects of aurintricarboxylic acid. Graefes Arch Clin Exp Ophthalmol 244:1512-1521. (Pubitemid 44741265)
15. Hughes RA, Swan AV, van Koningsveld R, van Doorn PA (2006). Corticosteroids for Guillain-Barre syndrome. Cochrane Database Syst Rev 2006:CD001446.
16. Huizenga NA, Koper JW, de Lange P, Pols HA, Stolk RP, Grobbee DE, de Jong FH, Lamberts SW (1998). Interperson variability but intraperson stability of baseline plasma cortisol concentrations, and its relation to feedback sensitivity of the hypothalamo-pituitary-adrenal axis to a low dose of dexamethasone in elderly individuals. J Clin Endocrinol Metab 83:47-54.
17. Jacobs BC, Rothbarth PH, van der Meché FG, Herbrink P, Schmitz PI, de Klerk MA, van Doorn PA (1998). The spectrum of antecedent infections in Guillain-Barre syndrome: a casecontrol study. Neurology 51:1110-1115. (Pubitemid 28473409)
18. Jacobs BC, Koga M, van Rijs W, Geleijns K, van Doorn PA, Willison HJ, Yuki N (2008). Subclass IgG to motor gangliosides related to infection and clinical course in Guillain-Barre syndrome. J Neuroimmunol 194: 181-190.
19. Jacobs BC, van Doorn PA, Schmitz PI, Tio-Gillen AP, Herbrink P, Visser LH, Hooijkass H, van der Meché FG (1996). Campylobacter jejuni infections and anti-GM1 antibodies in Guillain-Barre syndrome. Ann Neurol 40:181-187. (Pubitemid 26274553)
20. Jeanneteau F, Garabedian MJ, Chao MV (2008). Activation of Trk neurotrophin receptors by glucocorticoids provides a neuroprotective effect. Proc Natl Acad Sci USA 105: 4862-4867. (Pubitemid 351753837)
21. Kleyweg RP, van der Mech ́ e FG, Schmitz PI (1991). Interobserver agreement in the assessment of muscle strength and functional abilities in Guillain-Barre syndrome. Muscle Nerve 14:1103-1109.
22. McKay LI, Cidlowski JA (1999). Molecular control of immune/inflammatory responses: interactions between nuclear factor-kappa B and steroid receptor-signaling pathways. Endocr Rev 20:435-459.
23. Rautanen A, Eriksson JG, Kere J, Andersson S, Osmond C, Tienari P, Sairanen H, Barker DJ, Phillips DI, Forsen T, Kajantie E (2006). Associations of body size at birth with late-life cortisol concentrations and glucose tolerance are modified by haplotypes of the glucocorticoid receptor gene. J Clin Endocrinol Metab 91:4544-4551. (Pubitemid 44833437)
24. Stephens M, Smith NJ, Donnelly P (2001). A new statistical method for haplotype reconstruction from population data. Am J Hum Genet 68:978-989. (Pubitemid 32289743)
25. Stevens A, Ray DW, Zeggini E, John S, Richards HL, Griffiths CE, Donn R (2004). Glucocorticoid sensitivity is determined by a specific glucocorticoid receptor haplotype. J Clin Endocrinol Metab 89:892-897. (Pubitemid 38269907)
26. The Dutch Guillain-Barre Study Group (1994). Treatment of Guillain-Barre syndrome with high-dose immune globulins combined with methylprednisolone: a pilot study. Ann Neurol 35:749-752. (Pubitemid 24172177)
27. The Guillain-Barre Study Group (1985). Plasmapheresis and acute Guillain-Barre syndrome. Neurology 35:1096-1104.
28. van den Akker EL, Russcher H, van Rossum EF, Brinkmann AO, de Jong FH, Hokken A, Pols HA, Koper JW, Lamberts SW (2006a). Glucocorticoid receptor polymorphism affects transrepression but not transactivation. J Clin Endocrinol Metab 91:2800-2803. (Pubitemid 44024655)
29. van den Akker EL, Nouwen JL, Melles DC, van Rossum EF, Koper JW, Uitterlinden AG, Hofman A, Verbrugh HA, Pols HA, Lamberts SW, van Belkum A (2006b). Staphylococcus aureus nasal carriage is associatedwith glucocorticoid receptor gene polymorphisms. J Infect Dis 194:814-818. (Pubitemid 44344130)
30. van den Akker EL, Koper JW, van Rossum EF, Dekker MJ, Russcher H, de Jong FH, Uitterlinden AG, Hofman A, Pols HA, Witteman JC, Lamberts SW (2008). Glucocorticoid receptor gene and risk of cardiovascular disease. Arch Intern Med 168:33-39.
31. van der Mech ́ e FG, Schmitz PI (1992). A randomized trial comparing intravenous immune globulin and plasma exchange in Guillain-Barre syndrome. Dutch Guillain-Barre Study Group. N Engl J Med 326:1123-1129.
32. van Koningsveld R, Schmitz PI, van der Meché FG, Visser LH, Meulstee J, van Doorn PA (2004). Effect of methylprednisolone when added to standard treatment with intravenous immunoglobulin for Guillain-Barre syndrome: randomised trial. Lancet 363:192-196. (Pubitemid 38114716)
33. van Koningsveld R, Schmitz PI, Ang CW, Groen J, Osterhaus AD, van der Meché FG, Van Doorn PA (2002). Infections and course of disease in mild forms of Guillain-Barre syndrome. Neurology 58:610-614. (Pubitemid 34164944)
34. van Rossum EF, Lamberts SW (2004). Polymorphisms in the glucocorticoid receptor gene and their associations with metabolic parameters and body composition. Recent Prog Horm Res 59:333-357.
35. van Rossum EF, Roks PH, de Jong FH, Brinkmann AO, Pols HA, Koper JW, Lamberts SW (2004). Characterization of a promoter polymorphism in the glucocorticoid receptor gene and its relationship to three other polymorphisms. Clin Endocrinol 61:573-581.
36. van Rossum EF, Koper JW, van den Beld AW, Uitterlinden AG, Arp P, Ester W, Janssen JA, Brinkmann AO, de Jong FH, Grobbee DE, Pols HA, Lamberts SW (2003). Identification of the BcII polymorphism in the glucocorticoid receptor gene: association with sensitivity to glucocorticoids in vivo and body mass index. Clin Endocrinol 59:585-592. (Pubitemid 37357618)